Skip to main content
Premium Trial:

Request an Annual Quote

Invitae Partners With Prognos Health to Identify Rare Disease Patients, Treatments

NEW YORK – Prognos Health announced Wednesday that it entered into a data-sharing partnership with Invitae to identify rare disease patients, reduce their diagnostic journey, and improve access to effective therapies.

The collaborators will combine genetic testing results with lab and insurance claims data to drive earlier diagnoses and help pharmaceutical companies and other stakeholders improve treatment options for patients with rare disease through approaches such as designing more effective clinical trials and product launch strategies.

"By strategically aligning our comprehensive solutions, we aim to forge a seamless connection between real-world data and genetic insights," Prognos Health CEO Sundeep Bhan said in a statement.

Last year, New York-based Prognos Health also formed a strategic partnership with GeneDx to link newly diagnosed rare disease patients with therapies. Prognos had previously leveraged its machine learning capabilities to matching patients to therapies through a software license and laboratory data supply agreement with Biocept.